Building tools to predict stroke and memory problems in moyamoya disease
Follows people with moyamoya disease or syndrome to predict stroke and thinking decline.
Plain-language title generated from the registry record
Registry title: Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Key facts
- Where
- Beijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, and Zhengzhou, ChinaSee the 13 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 70 years old?
Source: NCT07894107, who can take part
Where in China
- Beijing Tiantan HospitalBeijing, ChinaTaking people
- Peking Union Medical College HospitalBeijing, ChinaNot yet recruiting
- The First Medical Center, Chinese PLA General HospitalBeijing, ChinaNot yet recruiting
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaNot yet recruiting
- West China Hospital，Sichuan UniversityChengdu, ChinaNot yet recruiting
- The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNot yet recruiting
- Children's Hospital Of Fudan UniversityShanghai, ChinaNot yet recruiting
- Huashan Hospital, Fudan UniversityShanghai, ChinaNot yet recruiting
- The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaNot yet recruiting
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaNot yet recruiting
- Henan Provincial People's HospitalZhengzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07894107
- Record updated
- 26 October 2026
- Original description
This multicenter prospective observational cohort study aims to develop and validate individualized risk prediction models for stroke and cognitive decline in patients with moyamoya disease or moyamoya syndrome by integrating clinical characteristics, laboratory data, multimodal neuroimaging, genetic information, and other available multidimensional data. Approximately 3,000 participants will be enrolled and followed for up to 24 months.Read full original descriptionShow less
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
This multicenter prospective observational cohort study aims to develop and validate individualized risk prediction models for stroke and cognitive decline in patients with moyamoya disease or moyamoya syndrome by integrating clinical characteristics, laboratory data, multimodal neuroimaging, genetic information, and other available multidimensional data. Approximately 3,000 participants will be enrolled and followed for up to 24 months.
Inclusion: Age 12 to 70 years; Diagnosis of moyamoya disease or moyamoya syndrome by DSA, CTA or MRA; Ability to complete neurological and cognitive assessments; Ability to complete at least 12 months of clinical follow-up and willingness, in principle, to complete 24 months of follow-up; At least one analyzable baseline vascular imaging examination in original DICOM format, including CTA, MRA, or DSA; Written informed consent provided by the participant and/or legally authorized representative.
Exclusion: Receipt of an investigational drug or device within 30 days before screening, or current participation in another interventional clinical trial that may interfere with this study; Previous cerebral revascularization surgery; Coexisting cerebrovascular malformation, intracranial tumor, hydrocephalus, or another disorder that may independently affect stroke or cognitive outcomes; Severe visual impairment, aphasia, impaired consciousness, psychiatric illness, or another disorder that prevents valid cognitive assessment, including Alzheimer's disease, Parkinson's disease, or frontotemporal dementia; Cardiac conditions that may cause cardioembolic stroke, including atrial fibrillation, patent foramen ovale or other right-to-left shunting cardiac disease, intracardiac mural thrombus, or infective endocarditis; or severe hepatic or renal dysfunction, coagulation disorders, malignancy, or severe cardiopulmonary disease; Refusal to participate or inability to complete follow-up; Pregnancy or breastfeeding.